Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SOX plus trastuzumab and sintilimab in HER2-positive locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR2200058732Phase 2Completed
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of oxaliplatin, tegafur, trastuzumab and sintilimab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: major pathological response. Started Apr 2022; status: completed.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2200058732.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058732.